Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on June 22, 2018, regarding events occurring on June 21, 2018. The filing details the entry into a material definitive underwriting agreement with A.G.P./Alliance Global Partners for a public offering of equity securities.
Key Financial Metrics and Transaction Details
The Company entered into an agreement to issue and sell the following securities at a public offering price of $0.90 per share for Common Stock and $1,000 per share for Preferred Stock:
- Common Stock: 4,350,000 shares.
- Series A Convertible Preferred Stock: 6,300 shares (convertible at $0.90/share).
- Series B Convertible Preferred Stock: 5,785 shares (convertible at $0.90/share).
Net Proceeds:
- Without over-allotment: Approximately $15,095,713.
- With full over-allotment exercise: Approximately $17,327,713.
Underwriting Compensation:
- Discount: 7% for new investors; 3.5% for investors with pre-existing relationships.
- Additional Compensation: 2% of aggregate shares issued (including conversion shares and option shares) in the form of Common Stock, subject to a 180-day lock-up.
Over-Allotment Option: The Underwriter holds a 45-day option to purchase up to 2,666,666 additional shares of Common Stock.
Material Changes and Lock-Up Provisions
The filing announces a significant capital raise and the creation of two new classes of convertible preferred stock. As part of the agreement, the Company, its officers, directors, and certain key shareholders have agreed to a 90-day lock-up period, during which they cannot sell or dispose of Common Stock without the Underwriter's written consent.
Guidance, Outlook, and Risks
Closing Date: The offering is expected to close on or about June 26, 2018, subject to customary conditions.
Ownership Limitations:
- Series A: Holders cannot convert if it results in beneficial ownership exceeding 4.99% (increasable to 9.99% with 61 days' notice).
- Series B: Holders cannot convert if it results in beneficial ownership exceeding 48%.
Risks and Contingencies: The transaction is subject to customary closing conditions and representations and warranties. The filing notes that the description of the Underwriting Agreement is qualified by reference to the full agreement filed as an exhibit.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received.
- Confirm the filing of the Certificates of Designation for Series A and Series B Preferred Stock with the Delaware Secretary of State.
- Monitor the exercise of the 45-day over-allotment option by the Underwriter.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Check for any subsequent filings regarding the use of proceeds.